奈妥吡坦 Netupitant
【化學(xué)名】奈妥吡坦 Netupitant
【原研】羅氏
【上市時(shí)間】2014年10月10日
【用途】用于治療惡心，嘔吐
【劑型/規(guī)格】膠囊 300mg;EQ 0.5mg BASE ；凍干 EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL ；靜脈注射液 EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)
奈妥吡坦Netupitant
一、產(chǎn)品概述
Netupitant奈妥匹坦，由羅氏首先研發(fā)，用于治療惡心、嘔吐；后由Helsinn研發(fā)其復(fù)方制劑奈妥吡坦/鹽酸帕洛諾司瓊。2014年10月10日，奈妥吡坦/鹽酸帕洛諾司瓊獲得FDA批準(zhǔn)，由赫爾辛醫(yī)療股份公司銷(xiāo)售，商品名為Akynzeo
二、主要產(chǎn)品
Description | Structural Formula | CAS No. | Category |
Netupitant |
| 290297-26-6 | API |
2-(3,5-bis(trifluoromethyl) phenyl)-2-methylpropanoic acid |
| 289686-70-0 | intermediates |
3-Pyridinecarboxamide, 4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- |
| 342417-01-0 | intermediates |
3-Pyridinamine,N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- |
| 290297-25-5 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.